Related Experiment Video
Updated: Jan 23, 2026
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
OGFRL1 Deficiency Causes Chronic Recurrent Multifocal Osteomyelitis Via Pathologic Osteoclastogenesis, With
Wen Xiong1, Yusha Wang2, Tingyan He3
1Department of Rheumatology and Immunology, Shenzhen Children's Hospital, Shenzhen, China.
Objective:
To verify the pathogenesis of the opioid growth factor receptor like-1 (OGFRL1) loss-of-function variant (c.30del, p. F10Ffs*110) identified in a patient with chronic recurrent multifocal osteomyelitis (CRMO) and to investigate the underlying mechanism.
Methods:
Whole exome sequencing and Sanger sequencing were performed to identify and confirm the variant. Quantitative polymerase chain reaction, enzyme-linked immunosorbent assay, cytometric bead assay, bulk RNA sequencing, and single-cell RNA sequencing were conducted to detect the inflammatory signatures of the patient versus healthy controls. A collagen antibody-induced arthritis (CAIA) model was generated in Ogfrl1 knockout (KO) and wild type (WT) mice, and micro-computed tomography scan was performed to investigate the pathogenicity of Ogfrl1 deficiency. In addition, osteoclast induction and differentiation in vitro was exerted to explore the underlying mechanism of Ogfrl1 deficiency.
Results:
The patient exhibited up-regulated mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways, along with overproduction of pro-inflammatory cytokines. Compared to healthy controls, apparent activation of myeloid cells was observed, especially in monocytes, dendritic cells, and low-density granulocytes (LDGs) of the patient. In the CAIA model, Ogfrl1 KO mice developed more severe and persistent arthritis and bone erosion than WT mice. Ogfrl1 KO mice were more prone to osteoclast differentiation than WT mice. The patient responded well to tumor necrosis factor inhibitor therapy, with normalization of C-reactive protein levels, erythrocyte sedimentation rate, serum amyloid A levels, and interleukin-6 levels, as well as improvement in osteolytic lesions.
Conclusion:
This study identified OGFRL1 deficiency as a novel cause of CRMO, highlighted the previously unrecognized role of OGFRL1 in restraining inflammatory responses, and provided novel insights into the pathogenesis and treatment of this autoinflammatory disorder.
More Related Videos
05:41Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
08:29Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
Related Concept Videos
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
01:13Therapeutic Index
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:30Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
01:29Microorganisms in Medicine and Therapeutics
01:26Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...